Duncan graduated with an MSc in Chemistry from Bristol University before gaining an MBA from UCLA. After working as Finance Director for a number of internet start-ups, Duncan moved into construction, joining Hong Kong based developers Tyler May where he rapidly rose to become head of international operations. Leaving to focus on his own portfolio, Duncan established himself as one of the shrewdest operators in the UK development arena, selling his business in 2001 for a profit of £11 million. Inspired by the Human Genome Project to return to his first love, biochemistry, he founded Prometha in 2002. Duncan also acts as a consultant for other businesses in the emerging genetic marketplace, giving talks and seminars around the globe.

BSc., PhD, organic chemistry with 20 years in clinical diagnostics, Tony replaced Markus Schoenberg as head of R&D in 2007. One of the most respected scientists in his field, Tony has held senior R&D positions at several US biotech firms and successfully steered the development track of two profitable new diagnostic companies. His particular interests are in immunodiagnostics and instrumentation. Tony joined Prometha from the Korean Institute of Biochemistry where he was head of genomic research for over six years.